Other Compounds

AURATEX

AuraTEX is a gold-based therapy that works with the immune system to aid in destroying different types of cancer.

Using the gold platform technology, AuraTEX can activate the immune system to help fight the growth and spread of cancer. The most innovative component of our gold compound is its mechanism of action. AuraTEX can destroy the cancer cells with 2 mechanisms of action:

Generating cancer-specific free radicals that, in turn, damage the endoplasmic reticulum and mitochondria inside the cancer. The mitochondria is the engine of the cells that creates energy.

The result of this damage is detected by the immune system. A cancer-specific immune response is then activated. The process results in the formation of tumor-specific killer T-cells that target and kill the remaining cancer[16].

.

MANGATEX

Tumor specific localization of MangaTEX allows for site selective thermal heating of breast cancer upon irradiation of non-tissue damaging light.

Breast cancer is the most common cancer globally[6].

Every year, about 340,000 women are diagnosed with both invasive and non-invasive breast cancer in the USA[7].

MangaTEX addresses an urgent unmet clinical need in breast cancer.

GEMTEX

GemTEX is being developed to treat pancreatic, bladder and other cancers.

GemTEX aims to minimize the side effects of chemotherapy and to increase drug concentration to the tumor.

Pancreatic cancer is the 11th most common cancer in the USA[8]. The 5 year survival rate is 10%[8].

Bladder cancer is 6th most common cancer with >82,000 cases each year in the USA[9].

More than 540,000 people have been diagnosed with bladder cancer globally[9].

GemTEX addresses an urgent unmet clinical need in locally advanced inoperable pancreatic cancer (LAPC) and bladder cancer.

PARPTEX

ParpTEX is being developed for prostate
and other BRCA mutant cancers.

ParpTEX aims to minimize the side effects of chemotherapy and to increase drug concentration to the tumor.

Prostate cancer is the 4th most common cancer globally[10].

Every year, over 210,000 men are diagnosed with prostate cancer in the USA[10].

ParpTEX addresses an urgent unmet clinical need in metastatic castration resistant prostate cancer.